Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company dedicated to the development of innovative powder-based intranasal therapies. The company’s primary focus is addressing acute medical conditions and urgent public health needs, utilizing proprietary microsphere technology to enable rapid, non-invasive drug delivery. Its product portfolio targets critical emergency situations, such as opioid overdose and anaphylactic shock, where immediate intervention is vital. Intranasal administration provides rapid absorption, ease of use, and does not require injection, making treatments more accessible to patients, caregivers, and first responders. Nasus Pharma’s technology has demonstrated significantly enhanced absorption rates compared to traditional solution-based drugs, supporting its relevance in life-threatening scenarios. Headquartered in Israel, the company’s work is particularly significant for advancing care standards in emergency medicine and holds potential for broader applications in the healthcare sector by improving the speed and effectiveness of drug delivery in acute settings.